论文部分内容阅读
目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)患者化疗前、后肿瘤组织中表皮生长因子受体(epidermal growth factor receptor,EGFR)基因外显子19和21的突变状况。方法:提取31例NSCLC患者化疗前、后肿瘤组织标本中的基因组DNA,采用巢式PCR技术扩增EGFR基因外显子19和21,并进行测序分析。结果:6例患者化疗前、后EGFR基因发生突变,其中4例为19号外显子发生缺失突变,2例为2l号外显子发生替代突变,且化疗前、后的突变状况一致。女性患者突变率(2/3)高于男性(4/28)(P=0.029),非吸烟者的突变率(4/9)高于吸烟者(2/22)(P=0.043)。结论:NSCLC组织EGFR基因外显子19和21突变在化疗前、后无明显改变。
Objective: To investigate the mutations of exon 19 and 21 of epidermal growth factor receptor (EGFR) gene in non-small cell lung cancer (NSCLC) patients before and after chemotherapy. Methods: The genomic DNA of 31 NSCLC patients before and after chemotherapy was extracted. The exon 19 and 21 of EGFR gene were amplified by nested PCR and sequenced. RESULTS: The EGFR gene mutations were found in 6 patients before and after chemotherapy. Four of them were deletion mutations in exon 19 and two in exon 2l. Mutations were similar before and after chemotherapy. The mutation rate was higher in women (2/3) than in men (4/28) (P = 0.029), and in nonsmokers (4/9) than in smokers (2/22) (P = 0.043). Conclusion: The mutations of exon 19 and 21 of EGFR gene in NSCLC tissues have no obvious changes before and after chemotherapy.